CLYM vs COAG: fair value comparison
Climb Bio, Inc. and Hemab Therapeutics Holdings, Inc. · Updated 2026-10-19
CLYM has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. COAG has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, CLYM currently ranks higher by quality score.
| CLYM | COAG | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $9.82 | $30.07 |
| 12-month range | $1.64–$17.84 | $27.13–$45.00 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #229 of 301 Healthcare | #231 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | Mixed | — |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: CLYM fair value analysis · COAG fair value analysis